There is one clinical trial.
The nutritional consequences of the infection by the SARS-CoV-2 are as follows: - A severe respiratory infection induces an inflammatory syndrome and hypercatabolism, as well as an increase in energy expenditure related to ventilatory work; nutritional requirements (calories and protein) are therefore increased. - Food intake is often reduced by several factors: anorexia secondary to infection, respiratory discomfort, anosmia, ageusia, obesity, stress, confinement, organizational problems limiting meal assistance. Then, it is important to asses the nutritional status of COVID patients hospitalized in conventional COVID units (excluding intensive care).
Description: The nutritional status of patients within the first 72 hours after hospital admission will be categorized according to the French Haute Authorité de Santé (France, 2019) non-malnourished patient moderately malnourished patient severely malnourished patientMeasure: Nutritional status of COVID infected patients Time: Up to 72 hours
Description: The supplemental oxygen requirement classified as follows: non-severe: no need of Oxygen light: 1 - 2 l/min moderate: 3 - 5 l/min severe: > 5 l/min critical: mechanical ventilationMeasure: Correlation between the nutritional status and the supplemental oxygen requirement Time: Up to 72 hours
Description: The prognostic after hospitalization will be classified as follows: Hospital discharge Transfer to the intensive care unit Transfer to other unit Follow-up care and rehabilitation DeathMeasure: Correlation between the nutritional status and the prognostic after hospitalization Time: Up to 72 hours
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports